Minimization of chronic plasma viremia in rhesus macaques immunized with synthetic HIV-1 Tat peptides and infected with a chimeric simian/human immunodeficiency virus (SHIV33).
about
Pivotal role of cyclic nucleoside phosphodiesterase 4 in Tat-mediated CD4+ T cell hyperactivation and HIV type 1 replicationHIV-1 Tat-based vaccines: an overview and perspectives in the field of HIV/AIDS vaccine development.SIVsm Tat, Rev, and Nef1: functional characteristics of r-GV internalization on isotypes, cytokines, and intracellular degradation.Tat-vaccinated macaques do not control simian immunodeficiency virus SIVmac239 replication.Tat-neutralizing antibodies in vaccinated macaques.AIDS vaccination studies with an ex vivo feline immunodeficiency virus model: analysis of the accessory ORF-A protein and DNA as protective immunogensInhibitory Effect of Individual or Combinations of Broadly Neutralizing Antibodies and Antiviral Reagents against Cell-Free and Cell-to-Cell HIV-1 Transmission.Fruit-specific expression of the human immunodeficiency virus type 1 tat gene in tomato plants and its immunogenic potential in mice.Problems and emerging approaches in HIV/AIDS vaccine development.Comparative study of Tat vaccine regimens in Mauritian cynomolgus and Indian rhesus macaques: influence of Mauritian MHC haplotypes on susceptibility/resistance to SHIV(89.6P) infection.Qualitative T-helper responses to multiple viral antigens correlate with vaccine-induced immunity to simian/human immunodeficiency virus infection.What does the structure-function relationship of the HIV-1 Tat protein teach us about developing an AIDS vaccine?Current status and perspectives of plant-based candidate vaccines against the human immunodeficiency virus (HIV).Outcome of simian-human immunodeficiency virus strain 89.6p challenge following vaccination of rhesus macaques with human immunodeficiency virus Tat protein.Prevention of disease induced by a partially heterologous AIDS virus in rhesus monkeys by using an adjuvanted multicomponent protein vaccine.Sequence variation within the dominant amino terminus epitope affects antibody binding and neutralization of human immunodeficiency virus type 1 Tat protein.Exploratory clinical studies of a synthetic HIV-1 Tat epitope vaccine in asymptomatic treatment-naïve and antiretroviral-controlled HIV-1 infected subjects plus healthy uninfected subjects.Tat HIV-1 primary and tertiary structures critical to immune response against non-homologous variants.
P2860
Q24684750-9EC12292-808A-4104-BBF5-A198B2FA4F75Q30381447-E575B659-8B4D-419F-A732-60AF74144E6DQ33636080-2273FB63-DDEA-4145-9798-43CAF598B0C2Q34336210-8676BF06-E072-4AA9-BE1C-02486B4AB7E6Q34755910-BDD85AEC-40CE-415D-9FC6-36AA3C371065Q35024266-AFA14045-1D13-4E4E-B7CE-C6EB00ACCD86Q35861276-B0806BC8-A516-466D-AA31-09B0E95A326CQ35946931-9B7B7EAB-92A0-4D83-B594-C5C75DBE9C6CQ36758574-7CF7F2EB-6DA3-4AB4-9D02-D249CDB14B67Q36961218-AE702DD2-5488-4EF3-AEB2-BBBC08A48A25Q37009569-860C450B-C798-4D0B-927E-8D95A6FFC510Q37220038-C8D30C78-34D6-46AE-9427-04D257330C0BQ37967232-5969BEA3-9CAA-462F-9AAB-939F9A8CCB28Q39683362-A87AE593-4DC3-413B-9626-6B9A016AA6E0Q39699309-B770B047-CA22-423F-9727-957FD9EA039FQ40273841-999029DB-376B-4EE9-A343-982EA3F22D3EQ44722017-D2F64302-ACE0-49BB-B5FF-676CEB700345Q46747253-4FF2E70B-9D71-4A01-BF13-D1EA4574F515
P2860
Minimization of chronic plasma viremia in rhesus macaques immunized with synthetic HIV-1 Tat peptides and infected with a chimeric simian/human immunodeficiency virus (SHIV33).
description
2000 nî lūn-bûn
@nan
2000年の論文
@ja
2000年学术文章
@wuu
2000年学术文章
@zh
2000年学术文章
@zh-cn
2000年学术文章
@zh-hans
2000年学术文章
@zh-my
2000年学术文章
@zh-sg
2000年學術文章
@yue
2000年學術文章
@zh-hant
name
Minimization of chronic plasma ...... munodeficiency virus (SHIV33).
@en
Minimization of chronic plasma ...... n/human immunodeficiency virus
@nl
type
label
Minimization of chronic plasma ...... munodeficiency virus (SHIV33).
@en
Minimization of chronic plasma ...... n/human immunodeficiency virus
@nl
prefLabel
Minimization of chronic plasma ...... munodeficiency virus (SHIV33).
@en
Minimization of chronic plasma ...... n/human immunodeficiency virus
@nl
P2093
P1433
P1476
Minimization of chronic plasma ...... munodeficiency virus (SHIV33).
@en
P2093
P304
P356
10.1016/S0264-410X(00)00085-2
P407
P577
2000-06-01T00:00:00Z